Document is current
Any future updates will be listed below
-
Authors
Schadt, Jonas https://orcid.org/0000-0002-2687-9178
von Bonin, Malte
Oelschlägel, Uta https://orcid.org/0000-0002-2287-437X
Teipel, Raphael
Epp, Katharina
Saalfeld, Felix Carl https://orcid.org/0000-0002-4095-8649
Schulze, Freya
Heuschkel, Sandra
Bornhäuser, Martin https://orcid.org/0000-0002-5916-3029
Röhnert, Maximilian Alexander https://orcid.org/0000-0001-8213-2047
-
Funding
Funding for this research was provided by:
Bundesministerium für Bildung, Wissenschaft, Forschung und Technologie (TRACK, #01KD25030)
Bundesministerium für Bildung, Wissenschaft, Forschung und Technologie (CAMINO, #01EO2101)
Technische Universität Dresden (MeDDrive #60534)
- License Information
-
More Information
Article History
Received: 16 October 2025
Revised: 17 February 2026
Accepted: 27 March 2026
First Online: 8 April 2026
Competing interests
: JS got research funding from TUD Dresden University of Technology (MeDDrive #60534). JS and MAR got a joint research grant from the German Federal Ministry of Research, Technology and Space (TRACK, #01KD25030). MvB was funded by the German Federal Ministry of Research, Technology and Space (CAMINO, #01EO2101). FCS received honoraria from Bristol Myers Squibb, Johnson & Johnson, and Pfizer. Although these companies are active in the field of CAR-T cell therapy and bispecific antibodies, these payments were not related to the present work. All other authors have no competing interests to declare.
: The trial was approved by the institutional review board at TUD Dresden University of Technology (IRB00001473, reference number BO-EK-66022024), and informed consent was obtained from all participants. All procedures involving patients or patient data were performed in accordance with the Declaration of Helsinki.
